trending Market Intelligence /marketintelligence/en/news-insights/trending/bTWmF4ebqmx207B_omR8mw2 content esgSubNav
In This List

Dr. Reddy's launches generic of Medicines Co.'s anti-coagulant in US

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Dr. Reddy's launches generic of Medicines Co.'s anti-coagulant in US

Dr. Reddy's Laboratories Ltd. launched its bivalirudin for injection, 250 milligrams/vial, in the U.S.

The drug is a generic version of the Medicines Co.'s Angiomax. Dr. Reddy's generic bivalirudin for injection was approved by the U.S. Food and Drug Administration in May.

Angiomax is a direct thrombin inhibitor indicated for use as an anti-coagulant in patients. The Angiomax brand and generic had U.S. sales of about $198 million moving annual total for the year ending March 2017, according to IMS Health data.